Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HK2 | P52789 | 5/20 | 0.50 |
| ▸ | HK1 | P19367 | 4/20 | 0.50 |
| ▸ | PYGB | P11216 | 7/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17547736 | 0.87 | KDM4E (0.52) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL17547733 | 0.87 | KDM4E (0.52) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL21401312 | 0.87 | KDM4E (0.52) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL16129445 | 0.87 | KDM4E (0.52) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL16129591 | 0.87 | KDM4E (0.52) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL23315864 | 0.87 | KDM4E (0.52) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL16129507 | 0.87 | KDM4E (0.52) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL22552555 | 0.86 | LMNA (0.57) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL15966274 | 0.86 | LMNA (0.57) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL29532523 | 0.86 | LMNA (0.57) | LMNAKDM4ECYP2D6CYP2C19HK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160257764-A1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | SYNAFFIX B.V. (NL) | 2016-09-08 | — | — | US | disclosed |
| US-20160235861-A1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | SynAffix. B.V. (NL) | 2016-08-18 | — | — | US | disclosed |
| WO-2015057066-A1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | SYNAFFIX B.V. (NL) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015057065-A1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | SYNAFFIX B.V. (NL) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257764-A1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | FUT5, FCGR1A, FCGR3B | LMNA 3204/4885KDM4E 2011/4885CYP2D6 1436/4885 |
| US-20160235861-A1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | FCGR1A, FCGR3B, FCGR2A | LMNA 2454/4885KDM4E 1753/4885CYP2D6 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.